Mosunetuzumab Clinical Trials
28 recruitingDrug
Phase 221Phase 18Phase 32
Showing 1–20 of 28 trials
Recruiting
Phase 3
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
Classic Follicular LymphomaFollicular Lymphoma With Unusual Cytological Features
National Cancer Institute (NCI)600 enrolled267 locationsNCT06337318
Recruiting
Phase 2
Mosunetuzumab and Zeprumetostat in Treating Patients With Follicular Lymphoma
Follicular Lymphoma
Institute of Hematology & Blood Diseases Hospital, China80 enrolled2 locationsNCT07555470
Recruiting
Phase 1
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
B-cell Non Hodgkin LymphomaRefractory B-Cell Non-Hodgkin LymphomaRelapsed B-Cell Non Hodgkin Lymphoma
ADC Therapeutics S.A.200 enrolled42 locationsNCT04970901
Recruiting
Phase 3
Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5
Follicular Lymphoma
The Lymphoma Academic Research Organisation790 enrolled116 locationsNCT06284122
Recruiting
Phase 2
Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial
Recurrent Follicular LymphomaRefractory Follicular LymphomaGrade 1 Follicular Lymphoma+2 more
University of Washington22 enrolled1 locationNCT06948786
Recruiting
Phase 1Phase 2
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
Refractory CancerB-cell LymphomaB-cell Malignancy+1 more
BeOne Medicines80 enrolled50 locationsNCT06634589
Recruiting
Phase 1
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Hoffmann-La Roche137 enrolled31 locationsNCT05091424
Recruiting
Phase 2
A Study to Evaluate Mosunetuzumab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis
Systemic Lupus ErythematosusLupusLupus Nephritis
Hoffmann-La Roche30 enrolled15 locationsNCT07598396
Recruiting
Phase 2
A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
Hodgkin LymphomaB-cell LymphomaRelapsed B-cell NHL
M.D. Anderson Cancer Center36 enrolled1 locationNCT05615636
Recruiting
Phase 2
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
LymphomaFollicular Lymphoma
Memorial Sloan Kettering Cancer Center152 enrolled9 locationsNCT05389293
Recruiting
Phase 2
Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial
Nodular Lymphocyte Predominant B-Cell LymphomaRecurrent Nodular Lymphocyte Predominant B-Cell LymphomaRefractory Nodular Lymphocyte Predominant B-Cell Lymphoma
National Cancer Institute (NCI)70 enrolled36 locationsNCT05886036
Recruiting
Phase 1
Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
High-grade B-cell LymphomaDiffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedTransformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
National Cancer Institute (NCI)30 enrolled8 locationsNCT06015880
Recruiting
Phase 2
Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Recurrent Transformed Chronic Lymphocytic LeukemiaRefractory Transformed Chronic Lymphocytic LeukemiaRecurrent Diffuse Large B-Cell Lymphoma+9 more
City of Hope Medical Center36 enrolled1 locationNCT05672251
Recruiting
Phase 1Phase 2
Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma
Diffuse Large B Cell LymphomaHigh-grade B-cell Lymphoma
OHSU Knight Cancer Institute30 enrolled1 locationNCT06249191
Recruiting
Phase 1
Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma
Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaB-cell Lymphoma+3 more
Washington University School of Medicine15 enrolled1 locationNCT05412290
Recruiting
Phase 1Phase 2
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
Relapsed/Refractory Non-Hodgkin Lymphoma
Bristol-Myers Squibb308 enrolled65 locationsNCT06090539
Recruiting
Phase 2
Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma
Ann Arbor Stage II Follicular LymphomaGrade 1 Follicular LymphomaAnn Arbor Stage III Follicular Lymphoma+6 more
University of Washington20 enrolled1 locationNCT06442475
Recruiting
Phase 2
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Diffuse Large B Cell LymphomaRecurrent Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell Lymphoma+4 more
SWOG Cancer Research Network396 enrolled87 locationsNCT05633615
Recruiting
Study to Evaluate the Response to Treatment With Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma (FL) After at Least Two Lines of Therapy, Within the Compassionate Use Program (CUP).
Relapsed/Refractory Follicular Lymphoma
Andrés José Maria Ferreri25 enrolled1 locationNCT07278921
Recruiting
Phase 2
A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma
Lymphoma
M.D. Anderson Cancer Center36 enrolled1 locationNCT06563505